In a presentation titled Readmission for Stroke and Quality of Care Among Hospitalized Patients With Transient Ischemic Attack: Real World Delivery of Care, Emily C. O'Brian, PhD, from Duke University School of Medicine, presented results from the American Heart Association's Get With the Guidelines (GWTG)-Stroke program. GWTG is a hospital improvement program designed to improve adherence to evidence-based care.
Among patients who have had transient ischemic attacks (TIAs), those who are in the highest risk category were least likely to receive optimal care to prevent future hospitalizations for TIA or stroke.
In a presentation; “Readmission for Stroke and Quality of Care Among Hospitalized Patients With Transient Ischemic Attack: Real World Delivery of Care,” Emily C. O’Brian, PhD, instructor, Duke University School of Medicine, presented results from the American Heart Association’s Get With the Guidelines (GWTG)-Stroke program.
Researchers used data for 58,809 TIA patients aged over 65 years enrolled in the GWTG-Stroke Registry (2003-2008). They estimated the risk for 1-year hospital admission for stroke or subsequent TIA using demographics and past medical history. The cohort was then divided into 5 groups based on their degree of risk. Researchers then assessed the quality of care based on 5 metrics reflecting whether eligible patients received: early antithrombotics, discharge antithrombotics, anticoagulants for patients with atrial fibrillation, anticoagulation therapy, statins for low-density lipoprotein cholesterol (LDL-C) levels greater than 100 mg/dL, and smoking cessation counseling. Researchers then calculated a defect-free care (DFC) measure to reflect the overall quality of care.
The study found the risk of readmission was 11.8% overall. Disparities between the lowest and highest risk categories were found for receipt of statins, anticoagulation therapy, smoking cessation counseling, and DFC. The quality-of-care metric for those with elevated LDL-C was least optimal. For the healthiest group of patients, approximately two-thirds received a statin. By comparison, approximately 56% received a statin.
The GWTG program is AHA’s hospital improvement program designed to improve adherence to evidence-based care. The program provides hospitals with a Web-based patient management tool, decision support, and real-time benchmarking capabilities. The GWTG-Stroke Fact Sheet can be found on the AHA website (https://www.heart.org/idc/groups/heart-public/@wcm/@private/@hcm/@gwtg/documents/downloadable/ucm_310976.pdf).
Dr O’Brian noted that protocols for optimal treatment are already in place to help remind healthcare providers of the appropriate care for a particular patient. “We already have a tool that reminds hospitals to follow recommendations ranging from hospital admission to helping the patient out the door,” Dr O’Brian said in an interview. However, more steps can be taken to ensure that the patients who are at highest risk are given the appropriate treatments. “Standard risk assessment delivery of optimal TIA patient care is needed.”
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More